What happened
Longevity startups raised significant funding in 2025, though the number of large deals was lower than in previous years. Many investments went to companies working on technologies like gene therapy, cellular reprogramming, and AI-driven health solutions. The sector continues to attract attention from both venture capital and strategic investors.
Why it matters
- The longevity sector is maturing, with capital increasingly focused on scalable platform technologies.
- Fewer mega-rounds suggest a shift toward more selective, strategic investments.
- Growing investment supports the development of new therapies and tools aimed at extending healthspan.
Key facts
- 1. Global investment in longevity companies reached $8.49 billion in 2024.
- 2. Longevity discovery platforms attracted $2.65 billion in 2024.
- 3. The number of deals declined slightly in 2024 despite the increase in total funding.
